Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of High-Dose Cefixime +/- Azithromycin in Healthy Volunteers
NCT02708992Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cefixime in gonorrhea, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Curve from 0 to infinity at Day 12, Peak Plasma Concentration at Day 12 and 4 more. Started Apr 2016; status: completed.
02
Drugs
cefixime
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT02708992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708992.